-
Je něco špatně v tomto záznamu ?
Three novel mutations in MODY and its phenotype in three different Czech families
Z. Bazalová, B. Rypácková, J. Broz, L. Brunerová, J. Polák, Z. Rusavý, L. Treslová, M. Andel,
Jazyk angličtina Země Irsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- diabetes mellitus farmakoterapie genetika MeSH
- dietoterapie MeSH
- fenotyp MeSH
- gliklazid terapeutické užití MeSH
- glukokinasa genetika MeSH
- hepatocytární jaderný faktor 1-alfa genetika MeSH
- hepatocytární jaderný faktor 4 genetika MeSH
- hypoglykemika MeSH
- inzulin terapeutické užití MeSH
- lidé MeSH
- mutace MeSH
- rodokmen MeSH
- výsledek terapie MeSH
- zdraví rodiny MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Československo MeSH
AIMS/HYPOTHESIS: MODY (Maturity Onset Diabetes of the Young) is an autosomal dominant inherited type of diabetes with significant genetic heterogeneity. New mutations causing MODY are still being found. A genetically confirmed diagnosis of MODY allows application of individualized treatment based on the underlying concrete genetic dysfunction. Detection of novel MODY mutations helps provide a more complete picture of the possible MODY genotypes. MATERIALS AND METHODS: We tested 43 adult Czech patients with clinical characteristics of MODY, using direct sequencing of HNF1A (hepatocyte nuclear factor 1-alpha), HNF4A (hepatocyte nuclear factor 4-alpha) and GCK (glucokinase) genes. RESULTS: In three Czech families we identified three novel mutations we believe causing MODY-two missense mutations in HNF1A [F268L (c.802T>C) and P291S (c.871C>T)] and one frame shift mutation in GCK V244fsdelG (c.729delG). Some of the novel HNF1A mutation carriers were successfully transferred from insulin to gliclazide, while some of the novel GCK mutation carriers had a good clinical response when switched from insulin or oral antidiabetic drugs to diet. CONCLUSION: We describe three novel MODY mutations in three Czech families. The identification of MODY mutations had a meaningful impact on therapy on the mutation carriers.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025937
- 003
- CZ-PrNML
- 005
- 20121212063512.0
- 007
- ta
- 008
- 120817e20100204ie f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.diabres.2010.01.005 $2 doi
- 035 __
- $a (PubMed)20132997
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 0_
- $a Bazalová, Zdenka. $7 _BN005313 $u 3rd Faculty of Medicine of Charles University, Centre of Research for Diabetes, Endocrinological Diseases and Clinical Nutrition, Ruská 87, 100 00 Prague 10, Czech Republic. bazalova@modydiabetes.cz
- 245 10
- $a Three novel mutations in MODY and its phenotype in three different Czech families / $c Z. Bazalová, B. Rypácková, J. Broz, L. Brunerová, J. Polák, Z. Rusavý, L. Treslová, M. Andel,
- 520 9_
- $a AIMS/HYPOTHESIS: MODY (Maturity Onset Diabetes of the Young) is an autosomal dominant inherited type of diabetes with significant genetic heterogeneity. New mutations causing MODY are still being found. A genetically confirmed diagnosis of MODY allows application of individualized treatment based on the underlying concrete genetic dysfunction. Detection of novel MODY mutations helps provide a more complete picture of the possible MODY genotypes. MATERIALS AND METHODS: We tested 43 adult Czech patients with clinical characteristics of MODY, using direct sequencing of HNF1A (hepatocyte nuclear factor 1-alpha), HNF4A (hepatocyte nuclear factor 4-alpha) and GCK (glucokinase) genes. RESULTS: In three Czech families we identified three novel mutations we believe causing MODY-two missense mutations in HNF1A [F268L (c.802T>C) and P291S (c.871C>T)] and one frame shift mutation in GCK V244fsdelG (c.729delG). Some of the novel HNF1A mutation carriers were successfully transferred from insulin to gliclazide, while some of the novel GCK mutation carriers had a good clinical response when switched from insulin or oral antidiabetic drugs to diet. CONCLUSION: We describe three novel MODY mutations in three Czech families. The identification of MODY mutations had a meaningful impact on therapy on the mutation carriers.
- 650 _2
- $a diabetes mellitus $x farmakoterapie $x genetika $7 D003920
- 650 _2
- $a dietoterapie $7 D004035
- 650 _2
- $a zdraví rodiny $7 D005192
- 650 _2
- $a gliklazid $x terapeutické užití $7 D005907
- 650 _2
- $a glukokinasa $x genetika $7 D005941
- 650 _2
- $a hepatocytární jaderný faktor 1-alfa $x genetika $7 D051538
- 650 _2
- $a hepatocytární jaderný faktor 4 $x genetika $7 D051557
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $7 D007004
- 650 _2
- $a inzulin $x terapeutické užití $7 D007328
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a rodokmen $7 D010375
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a výsledek terapie $7 D016896
- 651 _2
- $a Československo $7 D003604
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rypáčková, Blanka $7 xx0171714
- 700 1_
- $a Brož, Jan, $d 1963- $7 xx0046397
- 700 1_
- $a Brunerová, Ludmila $7 xx0106043
- 700 1_
- $a Polák, J
- 700 1_
- $a Rušavý, Zdeněk
- 700 1_
- $a Trešlová, Ludmila, $d 1946- $7 xx0081995
- 700 1_
- $a Anděl, Michal, $d 1946- $7 jn19981228006
- 773 0_
- $w MED00001385 $t Diabetes research and clinical practice $x 1872-8227 $g Roč. 88, č. 2 (20100204), s. 132-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20132997 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121212063553 $b ABA008
- 999 __
- $a ok $b bmc $g 947979 $s 783283
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 88 $c 2 $d 132-8 $e 20100204 $i 1872-8227 $m Diabetes research and clinical practice $n Diabetes Res Clin Pract $x MED00001385
- LZP __
- $a Pubmed-20120817/10/03